Saturday, November 6, 2021



Suven Pharma Q2 PAT up 30.91% at Rs96.98cr on EBITDA margin expanding 587 bps to 47.19%

Suven Pharma reported 26.79% growth in total revenues for the Sep-21 quarter on consolidated basis at Rs300.99cr

Suven Pharma reported 26.79% growth in total revenues for the Sep-21 quarter on consolidated basis at Rs300.99cr. The revenues were up 14.10% on a sequential basis compared to Rs263.80cr in the Jun-21 quarter.

Suven is focused on the contract development and manufacturing operations (CDMO) business. The export business of the company got impacted in the quarter due to a combination of supply chain constraints, higher input costs as well as the availability of vessels to export to other markets.

Net profits for the Sep-21 quarter were higher by 30.91% on yoy basis at Rs96.98cr. On a sequential basis, the net profit was lower by -7.71% compared to the Jun-21 quarter profits of Rs105.08cr.

Raw material costs were up 54% yoy at Rs118cr on account of input cost inflation and supply chain constraints. However, the inventory efficiency gains helped Suven to post 587 bps improvement in EBITDA margins to 47.19%.

Net margins at 32.22% in the Sep-21 quarter was higher than 31.21% in the Sep-20 yoy quarter but lower than 39.83% in Jun-21 sequential quarter.


88 is strong support zone and 134 is strong resistance zone for short term. Stock will remain sideways in this zone.

Disclaimer- The information on this blog are based on my personal opinion and experience, it should not be considered professional financial investment advice and in no way it should be considered as a tip. We does not take any compensation of any kind whatsoever from any reader, user and company that are mention on this website. We are not SEBI registered financial advisor or analyst.

No comments:

Post a Comment